Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of Salanersen for the treatment of spinal muscular atrophy (SMA).

Next Previous
Trial Profile

Phase 3 trial of Salanersen for the treatment of spinal muscular atrophy (SMA).

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIIB 115 (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions; Registrational

Most Recent Events

  • 02 Jul 2025 New trial record
  • 25 Jun 2025 According to an Ionis Pharmaceuticals media release, Biogen is currently engaging with global health authorities regarding the design of the Phase 3 studies. Ionis discovered salanersen and licensed the global development, manufacturing and commercialization rights to Biogen Inc.
  • 25 Jun 2025 According to Biogen media release, the company planning to initiate registrational trial based on Phase 1 trial data.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top